Table 4.

Evaluation of epidemiological and clinical variables according to IgG persistence 90 days after diagnosis

Variables		2nd IgG test		p
	N	Persistent n = 87 n (%)	Nonpersistent n = 38 n (%)
Sex
Female	83	56 (64.0)	27 (70.5)	0.6017*
Male	42	31 (36.0)	11 (29.5)
Age
< 60 years old	94	61 (73.3)	33 (85.3)	0.0773*
≥ 60 years old	31	26 (26.7)	5 (14.7)
Symptoms
Yes	123	87 (100)	36 (94.1)	0.1902**
No	02	0	2 (5.9)
Duration of symptoms
≤ 7 days	40	24 (26.7)	16 (50.0)	0.1424*
15 days	39	28 (33.7)	11 (29.4)
≥ 21 days	44	35 (39.6)	9 (20.6)
Hospitalization
Yes	11	10 (10.5)	1 (2.9)	0.1756*
No	114	77 (89.5)	37 (97.1)
Supplemental oxygen
Yes	11	10 (10.5)	1 (2.9)	0.1756**
No	114	77 (89.5)	37 (97.1)
H1N1 vaccine
Yes	106	71 (81.4)	35 (91.2)	0.1997**
No	19	16 (18.6)	3 (8.8)
BCG vaccine
Yes	102	71 (88.4)	31 (79.4)	0. 6766**
No	09	5 (5.8)	4 (11.8)
Unknown	08	5 (5.8)	3 (8.8)

*Chi-squared test; **G test